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Abstract: Complex I is a crucial respiratory enzyme that
conserves the energy from NADH oxidation by ubiquinone-10
(Q10) in proton transport across a membrane. Studies of its
energy transduction mechanism are hindered by the extreme
hydrophobicity of Q10, and they have so far relied on native
membranes with many components or on hydrophilic Q10
analogues that partition into membranes and undergo side
reactions. Herein, we present a self-assembled system without
these limitations: proteoliposomes containing mammalian
complex I, Q10, and a quinol oxidase (the alternative oxidase,
AOX) to recycle Q10H2 to Q10. AOX is present in excess, so
complex I is completely rate determining and the Q10 pool is
kept oxidized under steady-state catalysis. The system was used
to measure a fully-defined KM value for Q10. The strategy is
suitable for any enzyme with a hydrophobic quinone/quinol
substrate, and could be used to characterize hydrophobic
inhibitors with potential applications as pharmaceuticals,
pesticides, or fungicides.
Mitochondrial complex I (NADH:ubiquinone oxidoreduc-
tase) is a crucial energy-transducing respiratory enzyme. It
catalyzes NADH oxidation in the matrix and ubiquinone-10
(Q10) reduction in the inner membrane by a process coupled
to energy-conserving proton transfer across the membrane.[1]
The mechanism of NADH oxidation by the flavin-containing
active site has been characterized in detail by using soluble
electron acceptors. The mechanism of Q10 reduction, an
integral part of the unknown coupling mechanism, presents
a much greater challenge owing to the extreme hydropho-
bicity of Q10. Previous studies have addressed the effects of
inhibitors[2] and mutations in and around the substrate
binding site,[3, 4] and made use of spectroscopy to search for
ubiqsemiquinone intermediates.[5] However, they have relied
on either Q10 in native membranes
[5,6] (which contain many
different enzymes, thus complicating spectroscopic and
kinetic analyses) or on non-physiological hydrophilic Q10
analogues such as ubiquinone-1, ubiquinone-2 and decylubi-
quinone (DQ)[4, 7] (which must be added in excessive concen-
trations to maintain steady-state catalysis and that react
adventitiously at the flavin to generate damaging reactive
oxygen and semiquinone species[8]).
Proteoliposomes (PLs) are artificial phospholipid vesicles
into which membrane proteins are reconstituted to mimic
their natural environment. PLs suitable for kinetic and
spectroscopic studies of Q10 reduction by complex I require
Q10 in the membrane and co-reconstitution of an enzyme to
reoxidize Q10H2 (ubiquinol-10, reduced Q10). The alternative
oxidase (AOX) is a single-subunit quinol oxidase that
catalyzes Q10H2 oxidation and O2 reduction (but not proton
transfer across the membrane).[9] Herein, we present a new,
self-assembled respiratory membrane system (termed
Q10PLs) that contains mammalian complex I (from Bos
taurus), Q10 (its physiological substrate), and AOX (from
Trypanosoma brucei brucei ; see Scheme 1).
Table 1 presents the catalytic properties of Q10PLs formed
with a CI/Q10/AOX molar ratio of 1:800:26 (equal masses of
complex I and AOX; see the Supporting Information for
experimental details). The highest reported turnover numbers
for AOX and B. taurus complex I are approximately 500 and
330 s¢1, respectively[10,11] (assuming complex I comprises ca.
10% of the protein in mitochondrial membranes[12]). The high
CI/AOX ratio is intended to ensure that, during steady-state
catalysis, complex I is rate determining and the Q10 pool is
oxidized. First, to confirm that complex I is rate determining,
Scheme 1. Q10 cycling in the Q10PL membrane. Complex I (CI) oxidizes
NADH in the external solution and reduces Q10 to Q10H2 in the
membrane; AOX reoxidizes the Q10H2 and reduces O2 to H2O. k1 and
k2 are the rate constants for catalysis by complex I and AOX,
respectively.
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Q10PLs were prepared with half the usual amount of
complex I (Table S1 in the Supporting Information), and the
rate of catalysis was exactly halved. Second, Equation 1
(derived from Scheme 1) indicates that for a 1:26 ratio of
complex I and AOX with equal rate constants, the Q10 pool is
96% oxidized. Finally, complex I in Q10PLs catalyzes at up to
400 s¢1 (see Table 1), which is faster than in native membranes
(in which Q10H2 reoxidation is rate limiting).
Q10½ ¤
Q10 þ¤ ½Q10H2½ ¤ ¼
AOX½ ¤k2
CI½ ¤k1 þ AOX½ ¤k2 ð1Þ
Q10PLs allow direct comparison of complex I catalysis
using Q10 with catalysis using its hydrophilic analogue DQ.
[7]
Catalysis with 100 mm DQ (molar CI/DQ ratio 1:200,000) was
measured with Q10-free CI/AOX PLs, with AOX inhibited by
ascofuranone[14] to prevent DQH2 reoxidation. Complex I
turnover was three times slower than with Q10 (127 vs. 410 s
¢1,
see Table 1). However, the rate increased to 215 s¢1 when
AOX was allowed to oxidize DQH2 in the membrane, which
matches the rate of NADH:DQ oxidoreduction by the
detergent-solubilized complex I used to prepare the
(Q10)PLs (233 53 s¢1), and also the rate from (Q10)PLs
resolubilized by detergent addition. Therefore, steady-state
reduction of DQ by complex I in (Q10)PLs is hindered by
accumulation of DQH2 in the membrane and its slow
exchange for DQ across the membrane interface. Our results
highlight three important advantages of a reconstituted Q10
system for studying the quinone chemistry of complex I: the
rapid kinetics of Q10 reduction, the physiological relevance of
Q10, and the simplicity of having all of the Q10 species confined
to the membrane with no exchange across the membrane
interface.
There are two well-established methods for assessing
proton-motive force (Dp) formation by respiratory enzymes
in PLs, a central requirement for mechanistic studies. First,
substantial quenching of the fluorescence of 9-amino-6-
chloro-2-methoxyacridine (ACMA) during NADH oxidation
by Q10PLs indicates the formation of a substantial DpH
(Figure 1A).[15] Second, the respiratory control ratio (RCR) is
the ratio of the coupled and uncoupled rates of catalysis: Dp
opposes catalysis, so when an “uncoupler” is used to dissipate
Dp, the rate increases. The RCR value for NADH oxidation
by Q10PLs (1.1, 4 H
+ translocated per NADH) is low
compared to values reported for submitochondrial particles
(3.0–5.5,[11,12, 16] 10 H+ per NADH for complexes I, III, and IV)
and complex I containing PLs measured using DQ (2.2–
4.5,[17,18] 4 H+ per NADH) However, lower values are typical
for succinate oxidation by SMPs (1.6–3.2,[11, 12, 16] 6 H+ per
succinate from complexes II, III and IV), and the highest
value from inverted Escherichia coli vesicles that are known
to sustain Dp 160 mV[19] is 1.7[20] (6 H+ per NADH, from
complex I and an ubiquinol oxidase). Higher RCR values are
usually taken to indicate “better coupled” vesicles, but the
values are also affected by the enzyme activity and config-
uration. More highly active or tightly packed proton-pumping
enzymes are better able to compete with proton leak back
across the membrane, so they push Dp higher. During steady-
state catalysis, proton leak and translocation are equal and
opposite: because leak increases with Dp,[21] the more active
or packed enzyme reaches a higher Dp but displays a lower
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[a] Gramicidin is an ionophore that dissipates Dp. [b] Alamethicin is
a pore-forming antibiotic[13] that allows NADH access to the Q10PL
lumen. [c] Ascofuranone is an AOX inhibitor.[14] [d] MeanS.E.M.
(n=3).
Figure 1. Analyses of DpH formation and Q10 concentration in Q10PLs.
A) Formation of DpH across the PL membrane is demonstrated by
quenching of ACMA fluorescence. Gramicidin collapses Dp and the
fluorescence returns to its starting value. Conditions: 4 mgmL¢1 com-
plex I and 6 mgmL¢1 AOX in Q10PLs containing ca. 20 nmol Q10/mg
phospholipid in 10 mm Tris-SO4 (pH 7.5), 50 mm KCl, 75 mm KNO3,
and 0.5 mm ACMA, 32 8C. B) Spectroscopic determination of Q10
concentration in a Q10PL preparation. The spectra are from Q10PLs
that have been solubilized with 1% sodium dodecyl sulfate (SDS)
before (oxidized) and after (reduced) addition of 1.5 mm KBH4 to
reduce the Q10 to Q10H2. The intensity of the difference spectrum at
275 nm denotes the Q10 concentration. Concentrations present:
11.8 nm complex I, 0.6 mm AOX, 0.472 mgmL¢1 phospholipid, and
6.88 mm Q10 (calculated).
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RCR. Therefore, it is not currently possible to quantify theDp
sustained by complex I in Q10PLs. The pore-forming anti-
biotic alamethicin[13] was used in all subsequent experiments
to dissipate Dp and prevent it from confounding the results.
Q10PLs are a unique respiratory system because all of
their components are known and can be quantified (see the
Supporting Information). Complex I concentrations were
quantified using the flavin-catalyzed NADH:APAD+ oxido-
reduction reaction,[22] and AOX concentrations were taken to
be the difference between the total protein and complex I
concentrations. Phospholipid concentrations were quantified
by phosphate determination[23] and Q10 concentrations were
determined spectroscopically by measuring the absorbance
change upon addition of KBH4 (a reducing agent, see
Figure 1B).[24] Table S1 shows the values from a set of
Q10PLs containing different Q10 concentrations. Finally,
density-gradient centrifugation was used to check the homo-
geneity of a high-Q10 preparation of Q10PLs. Two distinct
bands were observed: the denser band contained approxi-
mately 80% of the phospholipid and roughly 90% of the
complex I. The vesicles in the less dense band may contain
less complex I because they became less saturated with
detergent during reconstitution. Crucially, both bands con-
tained the same phospholipid/Q10 ratio, so the minor inho-
mogeneity present was not considered significant.
Figure 2 shows the rate of NADH:O2 oxidoreduction by
complex I in Q10PLs as a function of Q10 concentration,
defined using the phospholipid concentration as a proxy for
the hydrophobic/membrane phase volume. The complex I/Q10
ratio is fixed in the preparation, so standard solution kinetic
analyses are not possible and each point is from an
independent preparation. The fact that the preparation with
half the usual complex I content has a matching rate of
turnover confirms that the rate is set only by the Q10
concentration (complex I is diluted in the membrane but
the Q10 concentration is constant). The data in Figure 2 were
fit to the Michaelis–Menten equation, giving aKM (Q10) value
for B. taurus complex I of 3.9 nmol/mg phospholipid (approx-
imately one Q10 molecule per 300 phospholipids). To our
knowledge this is the first steady-state KM measurement for
an enzyme and its native quinone, for which the quinone
substrate pool is held fully oxidized in every condition tested.
Previously, elegant single-turnover kinetics on Rhodobacter
complex III in chromatophores defined KM(Q10H2)= 3–5
Q10H2 per complex, but using a “collisional mechanism” in
which the rate is determined by [Q10H2] and unaffected by
[Q10].
[26] For complex I, a value of KM(Q10)= 2.4 1.7 nmol/
mg protein (consistent with our value) was reported using
pentane-extracted mitochondria (but with the redox state of
the Q pool undefined).[27]
Figure 2 also shows our value for complex I turnover in B.
taurus heart mitochondrial membranes that contain approx-
imately 12 nmol Q10/mg phospholipid (ca. 60 Q10 per com-
plexI; see Table S2). Because the membrane Q10 concentra-
tion is three times the complex I KM value, respiratory-chain
turnover in membranes is not limited at complex I by Q10 pool
concentration. The membrane data point in Figure 2 falls
below the curve owing to rate-limiting contributions from
complexes III and IV (which also render the Q10 pool partially
reduced).
The KM (Q10) value of 3.9 nmol Q10/mg phospholipid
equates to approximately 3.9 mm Q10 in the membrane phase
because 1 mg of phospholipid has a volume of around 1 mL.[28]
The value is high in comparison to values for enzymes that act
on soluble substrates, but Q10 is restricted to diffusion only
within the two-dimensional membrane bilayer, and the KM
tells us little about KD (only that KD 3.9 mm). With such
a high local Q10 concentration, there is no pressure on
complex I to evolve a lower KM, and matching KM to
concentration may help the system respond to changing
conditions. Furthermore, the high concentration creates
sufficient capacity to buffer changes to the Q10 pool potential,
and may facilitate antioxidant reactions that rely on the
(uncatalyzed) second-order reactions of Q10 and Q10H2 with
radical species.[29]
Q10PLs are independent respiratory units formed by self-
assembly from a mixture of phospholipids, Q10, complex I,
and AOX. Complex I (from B. taurus heart) and AOX (from
T. brucei) originate from very different sources and assemble
independently into Q10PLs, thus making non-physiological
supercomplex assemblies highly unlikely and imposing the
fluid mosaic model[30] on the membrane. The rapid rates of
catalysis observed support the interpretation that supercom-
plexes are not necessary for efficient catalysis and argue
further against a role for Q10 channeling within them.
[25]
Self-assembled artificial respiratory chains are suitable for
biophysical studies of any respiratory or photosynthetic
enzyme that uses a membrane-bound quinone substrate.
Historically, they were used to demonstrate the construction
of respiratory chains from individual enzymes and Q10, but
their capabilities have not (with very few exceptions[31]) been
exploited for detailed mechanistic studies. Furthermore,
many quinone antagonists are already used as pharmaceut-
icals or pesticides,[32, 33] and bioenergetic enzymes specific to
parasites and phytopathogenic fungi (including the alterna-
Figure 2. Q10 Michaelis–Menten curve for B. taurus complex I. The
rates of NADH oxidation from different Q10PL preparations are plotted
against the Q10 concentrations in the membranes and fit to the
Michalis–Menten equation with KM=3.94 nmol/mg phospholipid and
kcat=29.9 mmolmin
¢1/mg complex I=500 s¢1. Open square: Q10PL
preparation with half the standard amount of complex I. Open circle:
complex I in B. taurus mitochondrial membranes (rate of catalysis
enhanced by additional cytochrome c[25]). Conditions: 200 mm NADH,
15 mgmL¢1 alamethicin (Q10PLs only), 10 mm Tris-SO4 (pH 7.5), and
50 mm KCl, 32 8C. Values are the meanS.E.M. (n=3).
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tive NADH dehydrogenase and AOX) are being investigated
as drug targets.[34,35]Our self-assembled Q10PL system enables
candidate drugs and inhibitors to be competed against
physiologically relevant quinone substrates to provide prop-
erly defined and robust inhibitor dissociation constants for
translational research.
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